|
|
|
European Pharmaceutical Contractor
|
In the European Union, the paediatric population (0-16 years old) represents about 75 million people, a fifth of the total population. Although this population may appear relatively large, the majority of medicines are still only developed and assessed for use in adult populations. The absence of suitable authorised medicinal products to treat diseases in children has been an issue of concern for some time.
This is mainly a result of the failure of pharmaceutical companies to perform the necessary tests and trials to adapt medicinal products to the needs of children. It is estimated that over two thirds of patients admitted to paediatric wards in European hospitals received drugs prescribed in an unlicensed or off-label manner, not having been specifically evaluated for use in children. Consequently it leads to risks of inefficacy and/or adverse effects.
Pharmaceutical companies have traditionally been reluctant to invest in developing specific treatments or adapting existing medicines to meet the needs of the paediatric population, mainly because the market is small and therefore of lower priority to them - and the risks associated with paediatric treatments are generally higher (for example, need for long-term follow-up of adverse effects). In addition, the pharmaceutical industry tends not to develop specific paediatric formulations.
|
Read full article from PDF >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
Industry Events |
 |
World Vaccine Congress
10-12 April 2012, Gaylord National Hotel and Convention Center, Washington, US
The 12th annual World Vaccine Congress Washington brings new scientific and business critical debate, discussion and solutions from the true global pioneers shaping vaccine R&D.
More info >> |
|
 |
News and Press Releases |
 |
Topa Thermal Packaging introduces innovative pallet shipper
Topa Thermal Packaging has developed an innovative packaging for manufacturers that transport large quantities of temperature-sensitive products by road and air transport, such as vaccines and medicines. The ‘ClimateBox™ half PAG Pallet Shipper’ delivers significant time and cost savings, thanks to an efficient filling system.
More info >> |
|
|
